Trial Profile
Once-daily versus alternate-day rosuvastatin in patients with dyslipidaemias
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2012
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 22 May 2012 New trial record
- 18 Jan 2012 Primary endpoint 'C-reactive-protein' has been met.